Category Archives: Oncology Imaging

Imaging Biomarkers for Immunotherapy Response
21
Feb

Background

Immunotherapy can produce atypical response patterns such as pseudoprogression which complicates assessment by size alone. Imaging biomarkers including radiomics PET metrics and functional MRI parameters may provide earlier indicators of response or resistance. Robust validation is required before clinical adoption.

Candidate Biomarkers

PET based metrics of metabolic activity and radiomic texture features from CT or MRI have shown promise in early studies. Dynamic contrast MRI and diffusion metrics may reflect changes in tumor microenvironment and immune infiltration. Combining imaging biomarkers with blood based markers may improve predictive performance.

Clinical Trials and Validation

Prospective trials with standardized imaging protocols are needed to validate biomarkers and define thresholds for clinical decisions. Harmonization across scanners and reconstruction methods is essential for reproducibility. Regulatory qualification pathways should be pursued for biomarkers intended as trial endpoints.

Clinical Integration

Imaging biomarkers can inform early treatment modification and trial stratification when validated and standardized. Implement biomarker reporting with clear interpretation and recommended actions for clinicians. Multidisciplinary tumor boards should incorporate biomarker data into decision making.

Prostate Imaging
4
Feb

Overview

Prostate imaging includes MRI ultrasound and nuclear techniques for detection and staging. Multiparametric MRI is central to lesion detection and biopsy guidance. Imaging supports treatment planning and surveillance.

Multiparametric MRI

mpMRI combines T2 diffusion and perfusion sequences for lesion characterization. It improves detection of clinically significant cancer and guides targeted biopsy. Standardized reporting systems aid communication.

PET Tracers

Prostate specific membrane antigen PET improves detection of recurrent and metastatic disease. PSMA PET complements MRI and conventional imaging in staging. Tracer availability and interpretation expertise influence use.

Biopsy Guidance

MRI ultrasound fusion and targeted biopsy improve diagnostic yield. Imaging guided biopsy reduces sampling error and overdiagnosis. Coordination with urology ensures appropriate management.

Oncology Imaging
4
Feb

Overview

Oncology imaging uses CT MRI PET and ultrasound for staging and surveillance. It assesses tumor extent nodal involvement and metastases. Imaging guides biopsy radiation and surgical planning.

Staging and Response

Imaging determines stage and evaluates treatment response over time. Serial imaging helps assess tumor shrinkage progression or recurrence. Standardized criteria improve consistency in reporting.

Therapy Planning

Imaging supports radiation planning surgical resection and interventional therapies. Functional imaging can identify viable tumor and treatment targets. Multidisciplinary review integrates imaging into care decisions.

Surveillance

Post treatment surveillance uses modality specific protocols to detect recurrence early. Imaging intervals depend on tumor type stage and risk factors. Coordination with oncology ensures appropriate follow up.

Imaging for Sarcoma
4
Feb

Overview

Imaging characterizes sarcoma extent grade and relation to neurovascular structures. MRI is the modality of choice for soft tissue sarcomas while CT assesses bone involvement and staging. Multimodality imaging informs biopsy planning and surgical margins.

MRI Protocols

High resolution MRI with contrast delineates tumor extent and involvement of adjacent structures. Functional sequences may provide additional information about tumor biology. Standardized reporting supports surgical planning.

Staging and Surveillance

CT chest is essential for pulmonary metastasis assessment in sarcoma staging. PET CT may detect occult metastatic disease in select histologies. Surveillance imaging intervals are tailored to histology and risk.

Interventional and Surgical Planning

Image guided biopsy ensures representative sampling for histologic diagnosis. Imaging guides limb salvage surgery and reconstructive planning. Multidisciplinary sarcoma teams integrate imaging into comprehensive care.

Oncology Imaging Magazine
4
Feb

Overview

Oncology Imaging Magazine publishes articles on imaging biomarkers tumor characterization and response assessment; it emphasizes quantitative imaging and radiomics for precision oncology; multimodality approaches and trial imaging endpoints are featured.

Diagnostic and Staging

Articles evaluate CT MRI PET and hybrid imaging for staging and restaging; comparative studies assess sensitivity specificity and impact on management; protocol harmonization for trials is promoted.

Response and Surveillance

Coverage includes standardized response criteria volumetric assessment and functional biomarkers; early response indicators and pseudoprogression challenges are discussed; integration with clinical endpoints guides therapy decisions.

Translational Research

Radiogenomic and radiomic studies linking imaging phenotypes to molecular profiles are presented; prospective validation and reproducibility are emphasized; collaborative consortia and data sharing initiatives are highlighted.